<?xml version="1.0" encoding="utf-8"?>  
		   <iati-activities version="2.03" generated-datetime="2026-10-15T19:20:20">
		   <iati-activity last-updated-datetime="2026-10-15T19:20:20"
		   xml:lang="EN" default-currency="USD" hierarchy="01">
		   <iati-identifier>XI-IATI-WBTF-TF072627</iati-identifier>
		   <reporting-org ref="XI-IATI-WBTF" type="40">  
		   		   <narrative>World Bank Trust Funds</narrative>
		   </reporting-org>
		   <title>
		   <narrative>Support to International AIDS Vaccine Initiative (formerly known as the Support to IAVISendai Vector) SDTF Parallel to TF071457	   </narrative>
		   </title>
		   <description type="1">
		   <narrative>NA </narrative>
		   </description><participating-org ref="TF513001" type="10" role="1" >
       <narrative>Japan - Ministry of Finance </narrative>
       </participating-org><participating-org ref="XI-IATI-WBTF" type="40" role="4" >
       <narrative>World Bank Trust Funds </narrative>
       </participating-org> <activity-status code="3"></activity-status><activity-date type="1"  iso-date= "2016-06-06"></activity-date><activity-date type="2"  iso-date= "2016-06-06"></activity-date><activity-date type="3"  iso-date= "2019-03-31"></activity-date><activity-date type="4"  iso-date= "2019-05-28"></activity-date> <contact-info type="3">
       <organisation>
       <narrative></narrative>
       </organisation>
       <department>
       <narrative>HIS-Off. of VP &amp; Head of Network</narrative>
       </department>
       <person-name>
       <narrative></narrative>
       </person-name>
       <job-title>
       <narrative></narrative>
       </job-title>
       <telephone>1202-458-7916</telephone>
       <email></email>
       <mailing-address>
       <narrative>1818 H St, NW, Washington DC - 22036</narrative>
       </mailing-address>
       </contact-info><activity-scope code="1"></activity-scope> <recipient-region code="998">   <narrative>Bilateral unspecified</narrative>
       </recipient-region> <sector code="12110" 
	    vocabulary="1" percentage="100.00">
       <narrative>+![cdata[Health policy and administrative management]]+</narrative>
       </sector><collaboration-type code="2"></collaboration-type>
       <default-aid-type code="B03"></default-aid-type>
       <default-tied-status code="5"></default-tied-status><budget type="1">
       <period-start iso-date="2016-06-06"></period-start> 
       <period-end iso-date="2019-03-31"> </period-end>
       <value currency="USD" value-date="2026-03-31">4000000.00 </value>
       </budget><transaction>
	  <transaction-type code="1"></transaction-type>
       <transaction-date iso-date="2020-06-30"></transaction-date>
       <value currency="USD" value-date="2026-03-31">4000000.00  </value>
		   <description>
       <narrative>Incoming Funds (Cumulative Paid-In Contribution )-as of June 30th, 2020</narrative> 
       </description> 
	    <provider-org provider-activity-id="TF513001">
       <narrative>Japan - Ministry of Finance</narrative>
       </provider-org>
       <receiver-org receiver-activity-id="XI-IATI-WBTF-TF072627">
       <narrative>Support to International AIDS Vaccine Initiative (formerly known as the Support to IAVISendai Vector) SDTF Parallel to TF071457</narrative>
       </receiver-org>
       <finance-type code="110"></finance-type>
       </transaction><transaction>
	  <transaction-type code="11"></transaction-type>
       <transaction-date iso-date="2020-06-30"></transaction-date>
       <value currency="USD" value-date="2026-03-31">4000000.00  </value>
		   <description>
       <narrative>Incoming Commitment(Cumulative Signed Contribution)-as of June 30th, 2020</narrative> 
       </description> 
	    <provider-org provider-activity-id="TF513001">
       <narrative>Japan - Ministry of Finance</narrative>
       </provider-org>
       <receiver-org receiver-activity-id="XI-IATI-WBTF-TF072627">
       <narrative>Support to International AIDS Vaccine Initiative (formerly known as the Support to IAVISendai Vector) SDTF Parallel to TF071457</narrative>
       </receiver-org>
       <finance-type code="110"></finance-type>
       </transaction><transaction>
	  <transaction-type code="2"></transaction-type>
       <transaction-date iso-date="2020-06-30"></transaction-date>
       <value currency="USD" value-date="2026-03-31">207185.09  </value>
		   <description>
       <narrative>Allocation to Bank executed activities - as of June 30th, 2020</narrative> 
       </description> 
	    <provider-org provider-activity-id="XI-IATI-WBTF-TF072627">
       <narrative>Support to International AIDS Vaccine Initiative (formerly known as the Support to IAVISendai Vector) SDTF Parallel to TF071457</narrative>
       </provider-org>
       <receiver-org receiver-activity-id="XI-IATI-WBTF-P161232">
       <narrative>Bilateral, unspecified</narrative>
       </receiver-org>
       <finance-type code="110"></finance-type>
       </transaction><transaction>
	  <transaction-type code="2"></transaction-type>
       <transaction-date iso-date="2020-06-30"></transaction-date>
       <value currency="USD" value-date="2026-03-31">3593757.00  </value>
		   <description>
       <narrative>Outgoing Commitment ( Total Grant Allocated Amount to Project ) - as of June 30th, 2020</narrative> 
       </description> 
	    <provider-org provider-activity-id="XI-IATI-WBTF-TF072627">
       <narrative>Support to International AIDS Vaccine Initiative (formerly known as the Support to IAVISendai Vector) SDTF Parallel to TF071457</narrative>
       </provider-org>
       <receiver-org receiver-activity-id="XI-IATI-WBTF-P161232">
       <narrative>Bilateral, unspecified</narrative>
       </receiver-org>
       <finance-type code="110"></finance-type>
       </transaction><related-activity ref="XI-IATI-WBTF-P161232"  type="2"></related-activity>
   </iati-activity>	<iati-activity last-updated-datetime="2026-10-15T19:20:22"
	   xml:lang="EN" default-currency="USD" hierarchy="02">
       <iati-identifier>XI-IATI-WBTF-P161232</iati-identifier>
       <reporting-org ref="XI-IATI-WBTF"  type="40">
       <narrative>World Bank Trust Funds</narrative>
       </reporting-org>
       <title>
       <narrative> Support to Research and Development at the International AIDS Vaccine Initiative</narrative>
       </title>
       <description type="1">
       <narrative>The Project Development Objective is to support the International AIDS Vaccine Initiative (IAVI) in the optimization and testing ofone HIV vaccine candidate.  </narrative>
	   </description><participating-org ref="TF072627" type="40" role="4" >
       <narrative>Support to International AIDS Vaccine Initiative (formerly known as the Support to IAVI-Sendai Vector) SDTF - Parallel to TF071457 </narrative>
       </participating-org><participating-org ref="TF513001" type="10" role="1" >
       <narrative>Japan - Ministry of Finance </narrative>
       </participating-org> <activity-status code="3"></activity-status><activity-date type="1"  iso-date= "2016-08-22"></activity-date><activity-date type="2"  iso-date= "2016-08-22"></activity-date><activity-date type="3"  iso-date= "2019-03-31"></activity-date><activity-date type="4"  iso-date= "2019-05-02"></activity-date> <contact-info type="2">
       <organisation>
       <narrative></narrative>
       </organisation>
       <department>
       <narrative></narrative>
       </department>
       <person-name>
       <narrative>Mr Robert Oelrichs</narrative>
       </person-name>
       <job-title>
       <narrative>Short Term Consultant</narrative>
       </job-title>
       <telephone>1202-458-7916</telephone>
       <email></email>
       <mailing-address>
       <narrative>1818 H St, NW, Washington DC - 22036</narrative>
       </mailing-address>
       </contact-info><activity-scope code="1"></activity-scope> <recipient-region code="998">   <narrative>Bilateral unspecified</narrative>
       </recipient-region> <sector code="12110"  vocabulary="1" percentage="100.00">
       <narrative>+![cdata[Health policy and administrative management]]+</narrative>
       </sector><collaboration-type code="2"></collaboration-type>
       <default-aid-type code="C01"></default-aid-type>
       <default-tied-status code="5"></default-tied-status><budget type="1">
       <period-start iso-date="2016-08-22"></period-start> 
       <period-end iso-date="2019-03-31"> </period-end>
       <value currency="USD" value-date="2026-03-31">3800942.09 </value>
       </budget><transaction>
	  <transaction-type code="11"></transaction-type>
       <transaction-date iso-date="2020-06-30"></transaction-date>
       <value currency="USD" value-date="2026-03-31">207185.09  </value>
		   <description>
       <narrative>Allocation to Bank executed activities - as of June 30th, 2020</narrative> 
       </description> 
	    <provider-org provider-activity-id="XI-IATI-WBTF-TF072627">
       <narrative>Support to International AIDS Vaccine Initiative (formerly known as the Support to IAVI-Sendai Vector) SDTF - Parallel to TF071457</narrative>
       </provider-org>
       <receiver-org receiver-activity-id="P161232">
       <narrative>Bilateral, unspecified</narrative>
       </receiver-org>
       <finance-type code="110"></finance-type>
       </transaction><transaction>
	  <transaction-type code="11"></transaction-type>
       <transaction-date iso-date="2020-06-30"></transaction-date>
       <value currency="USD" value-date="2026-03-31">3593757.00  </value>
		   <description>
       <narrative>Incoming Commitment (Total Grant Allocated Amount) - as of June 30th, 2020</narrative> 
       </description> 
	    <provider-org provider-activity-id="XI-IATI-WBTF-TF072627">
       <narrative>Support to International AIDS Vaccine Initiative (formerly known as the Support to IAVI-Sendai Vector) SDTF - Parallel to TF071457</narrative>
       </provider-org>
       <receiver-org receiver-activity-id="P161232">
       <narrative>Bilateral, unspecified</narrative>
       </receiver-org>
       <finance-type code="110"></finance-type>
       </transaction><transaction>
	  <transaction-type code="3"></transaction-type>
       <transaction-date iso-date="2020-06-30"></transaction-date>
       <value currency="USD" value-date="2026-03-31">3593757.00  </value>
		   <description>
       <narrative>Disbursement(Total Recipient-Executed Trust Funds Disbursements ) - as of June 30th, 2020</narrative> 
       </description>
	    <provider-org provider-activity-id="XI-IATI-WBTF">
       <narrative>World Bank Trust Funds</narrative>
       </provider-org>
       <receiver-org receiver-activity-id="XI-IATI-WBTF-P161232">
       <narrative></narrative>
       </receiver-org>
       <finance-type code="110"></finance-type>
       </transaction><transaction>
	  <transaction-type code="4"></transaction-type>
       <transaction-date iso-date="2020-06-30"></transaction-date>
       <value currency="USD" value-date="2026-03-31">207185.09  </value>
		   <description>
       <narrative>Cumulative Expenditures to Bank executed activities - as of June 30th, 2020</narrative> 
       </description>
	    <provider-org provider-activity-id="XI-IATI-WBTF">
       <narrative>World Bank Trust Funds</narrative>
       </provider-org>
       <receiver-org receiver-activity-id="XI-IATI-WBTF-P161232">
       <narrative></narrative>
       </receiver-org>
       <finance-type code="110"></finance-type>
       </transaction><related-activity ref="XI-IATI-WBTF-TF072627" type="1"></related-activity><result type="2" aggregation-status="0">
<title><narrative>
 PDO Indicator 
</narrative></title>

								<indicator measure="5" ascending="1">

															<title><narrative>
Vector has been optimized
</narrative></title> 
<baseline year="2016" iso-date="2016-07-04" value="No"><comment>
					<narrative></narrative></comment></baseline>

																	<period>
																	<period-start iso-date="2016-07-04" />  <period-end iso-date="2017-06-30" />
<target value="Yes">


																	</target>

																	<actual value="Yes">


																	</actual>

																	</period>
</indicator>
</result><result type="2" aggregation-status="0">
<title><narrative>
 PDO Indicator 
</narrative></title>

								<indicator measure="5" ascending="1">

															<title><narrative>
Vector testing has been initiated
</narrative></title> 
<baseline year="2016" iso-date="2016-07-04" value="No"><comment>
					<narrative></narrative></comment></baseline>

																	<period>
																	<period-start iso-date="2016-07-04" />  <period-end iso-date="2017-06-30" />
<target value="Yes">


																	</target>

																	<actual value="Yes">


																	</actual>

																	</period>
</indicator>
</result><result type="1" aggregation-status="0">
<title><narrative>
 Intermediate Results Indicator 
</narrative></title>

								<indicator measure="5" ascending="1">

															<title><narrative>
Five genetically modified VSVdG-Env.BG505 vaccines have been isolated and characteristics have been analyzed
</narrative></title> 
<baseline year="2017" iso-date="2017-02-10" value="No"><comment>
					<narrative></narrative></comment></baseline>

																	<period>
																	<period-start iso-date="2017-02-10" />  <period-end iso-date="2017-06-30" />
<target value="Yes">


																	</target>

																	<actual value="Yes">


																	</actual>

																	</period>
</indicator>
</result><result type="1" aggregation-status="0">
<title><narrative>
 Intermediate Results Indicator 
</narrative></title>

								<indicator measure="5" ascending="1">

															<title><narrative>
VSVdG-Env.BG505 mutants have been isolated after serial passage under conditions that select for viruses with increased replicativefitness. Mutant virus characteristics have been analyzed.
</narrative></title> 
<baseline year="2017" iso-date="2017-02-10" value="No"><comment>
					<narrative></narrative></comment></baseline>

																	<period>
																	<period-start iso-date="2017-02-10" />  <period-end iso-date="2017-06-30" />
<target value="Yes">


																	</target>

																	<actual value="Yes">


																	</actual>

																	</period>
</indicator>
</result><result type="1" aggregation-status="0">
<title><narrative>
 Intermediate Results Indicator 
</narrative></title>

								<indicator measure="5" ascending="1">

															<title><narrative>
Candidate vaccines have been produced for a preclinical study.
</narrative></title> 
<baseline year="2017" iso-date="2017-02-10" value="No"><comment>
					<narrative></narrative></comment></baseline>

																	<period>
																	<period-start iso-date="2017-02-10" />  <period-end iso-date="2017-06-30" />
<target value="Yes">


																	</target>

																	<actual value="Yes">


																	</actual>

																	</period>
</indicator>
</result><result type="1" aggregation-status="0">
<title><narrative>
 Intermediate Results Indicator 
</narrative></title>

								<indicator measure="5" ascending="1">

															<title><narrative>
A decision to test new VSVdG-Env.BG505 vaccines or revise a macaque study to evaluate the requirement for three doses have been made.
</narrative></title> 
<baseline year="2017" iso-date="2017-02-10" value="No"><comment>
					<narrative></narrative></comment></baseline>

																	<period>
																	<period-start iso-date="2017-02-10" />  <period-end iso-date="2017-06-30" />
<target value="Yes">


																	</target>

																	<actual value="Yes">


																	</actual>

																	</period>
</indicator>
</result><result type="2" aggregation-status="0">
<title><narrative>
 PDO Indicator 
</narrative></title>

								<indicator measure="5" ascending="1">

															<title><narrative>
Additional viral vectors have been developed
</narrative></title> 
<baseline year="2017" iso-date="2017-09-06" value="No"><comment>
					<narrative></narrative></comment></baseline>

																	<period>
																	<period-start iso-date="2017-09-06" />  <period-end iso-date="2018-06-30" />
<target value="Yes">


																	</target>

																	<actual value="No">


																	</actual>

																	</period>
</indicator>
</result><result type="1" aggregation-status="0">
<title><narrative>
 Intermediate Results Indicator 
</narrative></title>

								<indicator measure="5" ascending="1">

															<title><narrative>
Feasibility of VERO-CD4/CCR5 cell line also expressing VSV glycoprotein G is demonstrated
</narrative></title> 
<baseline year="2017" iso-date="2017-06-20" value="No"><comment>
					<narrative></narrative></comment></baseline>

																	<period>
																	<period-start iso-date="2017-06-20" />  <period-end iso-date="2018-06-30" />
<target value="Yes">


																	</target>

																	<actual value="No">


																	</actual>

																	</period>
</indicator>
</result><result type="1" aggregation-status="0">
<title><narrative>
 Intermediate Results Indicator 
</narrative></title>

								<indicator measure="5" ascending="1">

															<title><narrative>
Conduct serial passage of VSV New Jersey vector to improve replicative capacity and fitness of the virus
</narrative></title> 
<baseline year="2017" iso-date="2017-06-20" value="No"><comment>
					<narrative></narrative></comment></baseline>

																	<period>
																	<period-start iso-date="2017-06-20" />  <period-end iso-date="2018-06-30" />
<target value="Yes">


																	</target>

																	<actual value="No">


																	</actual>

																	</period>
</indicator>
</result><result type="1" aggregation-status="0">
<title><narrative>
 Intermediate Results Indicator 
</narrative></title>

								<indicator measure="5" ascending="1">

															<title><narrative>
Evaluate VSV New Jersey vector for improved fitness and utility as a vaccine platform
</narrative></title> 
<baseline year="2017" iso-date="2017-06-20" value="No"><comment>
					<narrative></narrative></comment></baseline>

																	<period>
																	<period-start iso-date="2017-06-20" />  <period-end iso-date="2018-06-30" />
<target value="Yes">


																	</target>

																	<actual value="No">


																	</actual>

																	</period>
</indicator>
</result><result type="1" aggregation-status="0">
<title><narrative>
 Intermediate Results Indicator 
</narrative></title>

								<indicator measure="5" ascending="1">

															<title><narrative>
Initiate VERO CD4/CCR5 VSV G expressing cell line in Early Development Laboratory
</narrative></title> 
<baseline year="2017" iso-date="2017-09-06" value="No"><comment>
					<narrative></narrative></comment></baseline>

																	<period>
																	<period-start iso-date="2017-09-06" />  <period-end iso-date="2018-09-28" />
<target value="No">


																	</target>

																	<actual value="No">


																	</actual>

																	</period>
</indicator>
</result><result type="1" aggregation-status="0">
<title><narrative>
 Intermediate Results Indicator 
</narrative></title>

								<indicator measure="5" ascending="1">

															<title><narrative>
Organize and facilitate meeting in conjunction with UHC Forum in December in Tokyo on Japanese investments in global health R&amp;D
</narrative></title> 
<baseline year="2017" iso-date="2017-09-06" value="No"><comment>
					<narrative></narrative></comment></baseline>

																	<period>
																	<period-start iso-date="2017-09-06" />  <period-end iso-date="2018-06-30" />
<target value="Yes">


																	</target>

																	<actual value="No">


																	</actual>

																	</period>
</indicator>
</result><result type="1" aggregation-status="0">
<title><narrative>
 Intermediate Results Indicator 
</narrative></title>

								<indicator measure="5" ascending="1">

															<title><narrative>
Preclinical study in non-human primates has been commenced.
</narrative></title> 
<baseline year="2017" iso-date="2017-02-10" value="No"><comment>
					<narrative></narrative></comment></baseline>

																	<period>
																	<period-start iso-date="2017-02-10" />  <period-end iso-date="2017-06-30" />
<target value="Yes">


																	</target>

																	<actual value="Yes">


																	</actual>

																	</period>
</indicator>
</result><result type="2" aggregation-status="0">
<title><narrative>
 PDO Indicator 
</narrative></title>

								<indicator measure="5" ascending="1">

															<title><narrative>
VSVdG-Env.BG505.1 vaccine vector has been evaluated
</narrative></title> 
<baseline year="2017" iso-date="2017-09-06" value="No"><comment>
					<narrative></narrative></comment></baseline>

																	<period>
																	<period-start iso-date="2017-09-06" />  <period-end iso-date="2018-06-30" />
<target value="Yes">


																	</target>

																	<actual value="No">


																	</actual>

																	</period>
</indicator>
</result><result type="1" aggregation-status="0">
<title><narrative>
 Intermediate Results Indicator 
</narrative></title>

								<indicator measure="5" ascending="1">

															<title><narrative>
Determination of construction feasibility and replicative capacity of VSVdG-Env.BG505 with Env in position 2, 3 or 5
</narrative></title> 
<baseline year="2017" iso-date="2017-06-20" value="No"><comment>
					<narrative></narrative></comment></baseline>

																	<period>
																	<period-start iso-date="2017-06-20" />  <period-end iso-date="2018-06-30" />
<target value="Yes">


																	</target>

																	<actual value="No">


																	</actual>

																	</period>
</indicator>
</result><result type="1" aggregation-status="0">
<title><narrative>
 Intermediate Results Indicator 
</narrative></title>

								<indicator measure="5" ascending="1">

															<title><narrative>
VSVdG-Env.BG505 position 1 vector with Matrix protein (M) modifications that will dampen the innate immune response rescued
</narrative></title> 
<baseline year="2017" iso-date="2017-06-20" value="No"><comment>
					<narrative></narrative></comment></baseline>

																	<period>
																	<period-start iso-date="2017-06-20" />  <period-end iso-date="2018-09-28" />
<target value="No">


																	</target>

																	<actual value="No">


																	</actual>

																	</period>
</indicator>
</result><result type="1" aggregation-status="0">
<title><narrative>
 Intermediate Results Indicator 
</narrative></title>

								<indicator measure="5" ascending="1">

															<title><narrative>
VSVdG-Env.BG505.1 vector with M modifications evaluated for genetic stability and replicative capacity
</narrative></title> 
<baseline year="2017" iso-date="2017-06-20" value="No"><comment>
					<narrative></narrative></comment></baseline>

																	<period>
																	<period-start iso-date="2017-06-20" />  <period-end iso-date="2018-09-28" />
<target value="No">


																	</target>

																	<actual value="No">


																	</actual>

																	</period>
</indicator>
</result><result type="1" aggregation-status="0">
<title><narrative>
 Intermediate Results Indicator 
</narrative></title>

								<indicator measure="5" ascending="1">

															<title><narrative>
Initiate VSVdG-Env.BG505 position 1 vector vaccine rescue in Early Development Laboratory
</narrative></title> 
<baseline year="2017" iso-date="2017-06-20" value="No"><comment>
					<narrative></narrative></comment></baseline>

																	<period>
																	<period-start iso-date="2017-06-20" />  <period-end iso-date="2018-09-28" />
<target value="No">


																	</target>

																	<actual value="No">


																	</actual>

																	</period>
</indicator>
</result></iati-activity></iati-activities>